Lytix Biopharma
Develops oncolytic immunotherapies for people with cancer
Highlights
- New on EvolcAdded 2026-10-28
About Lytix Biopharma
Lytix Biopharma develops oncolytic molecule therapies for superficial and deep-seated tumors. Its pipeline includes ruxotemitide for resectable melanoma and LTX-401 for deep-seated solid tumors.
The company is pursuing co-development and outlicensing partnerships. Ruxotemitide is being evaluated with pembrolizumab in an investigator-led Phase 2 study in patients with resectable melanoma before surgery.
Lytix Biopharma was founded in 2003 and is headquartered in Oslo.
Product: A pipeline of oncolytic immunotherapies, including ruxotemitide and LTX-401.
Jobs at Lytix Biopharma
No open positions listed right now.
More biotech & pharma companies
Marine Spark X
Develops sea urchin-derived marine products for supplement and bioactive applications, using resources from Northern NorwayYoung companyNew on EvolcNextera
Discovers TCR-like antibody drug candidates against disease-specific pHLA targets for cancer and autoimmune diseaseNew on EvolcNocteva
Organoid models and drug discovery services for rare disease researchers and biotech companiesYoung companyNew on EvolcNorsk Medisinsk Syklotronsenter
Makes short-lived PET radiopharmaceuticals for diagnostic imaging, serving clinics and pharma partners from OsloNew on EvolcNuclithera
Targeted radiopharmaceuticals for patients with metastatic and difficult-to-treat cancersYoung companyNew on EvolcNykode Therapeutics
Develops immunotherapies for patients with cancer and autoimmune diseases using a modular biotech platformNew on Evolc
.png){kind=small}
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Next.js
- React
- Vercel